We are live on !
Find out more
LPC
Lion Point Capital Portfolio holdings
AUM
$20.9M
Turnover
0%
1-Year Est. Return
195.52%
This Fund
S&P 500
This Quarter Est. Return
+58.26%
1 Year Est. Return
+195.52%
3 Year Est. Return
+318.83%
5 Year Est. Return
+369%
10 Year Est. Return
+2,361.28%
AUM
$20.9M
AUM Growth
+$4.17M
(+25%)
Cap. Flow
-$463K
Cap. Flow % of AUM
Cap. Flow %
-2.22%
Top 10 Holdings %
Top 10 Hldgs %
55.01%
Holding
35
New
–
Increased
–
Reduced
1
Closed
–
Avg Time Held
1.4
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
1.2
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cue Biopharma
CUE
|
+$463K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Cue Biopharma
CUE
$117M
| $1.67M | 7.99% |
52,928
-20,500
| -28% | -$463K |
2025 Q4
2 quarters
|
|
2
Praxis Precision Medicines
PRAX
$7.26B
| $1.49M | 7.13% |
4,450
| – | – |
2025 Q3
3 quarters
|
|
3
MoonLake Immunotherapeutics
MLTX
$830M
| $1.31M | 6.29% |
67,500
| – | – |
2025 Q3
3 quarters
|
|
4
Fennec Pharmaceuticals
FENC
$360M
| $1.21M | 5.78% |
112,434
| – | – |
2023 Q2
12 quarters
|
|
5
Royalty Pharma
RPRX
$26.8B
| $1.2M | 5.74% |
21,400
| – | – |
2025 Q3
3 quarters
|
|
6
Compass Pathways
CMPS
$1.54B
| $1.13M | 5.41% |
80,000
| – | – |
2025 Q3
3 quarters
|
|
7
Milestone Pharmaceuticals
MIST
$87.2M
| $1.1M | 5.26% |
820,000
| – | – |
2022 Q1
17 quarters
|
|
8
Benitec Biopharma
BNTC
$292M
| $830K | 3.97% |
62,000
| – | – |
2024 Q3
7 quarters
|
|
9
Syndax Pharmaceuticals
SNDX
$1.17B
| $787K | 3.76% |
36,000
| – | – |
2023 Q2
12 quarters
|
|
10
Biohaven
BHVN
$1.71B
| $769K | 3.68% |
51,700
| – | – |
2024 Q3
7 quarters
|
|
11
Geron
GERN
$771M
| $740K | 3.54% |
578,000
| – | – |
2024 Q1
9 quarters
|
|
12
uniQure
QURE
$1.54B
| $677K | 3.24% |
14,700
| – | – |
2025 Q4
2 quarters
|
|
13
Ardelyx
ARDX
$798M
| $656K | 3.14% |
128,650
| – | – |
2022 Q3
15 quarters
|
|
14
Lantheus
LNTH
$6.52B
| $610K | 2.92% |
5,500
| – | – |
2025 Q4
2 quarters
|
|
15
Disc Medicine
IRON
$3.03B
| $592K | 2.83% |
8,100
| – | – |
2024 Q3
7 quarters
|
|
16
Sarepta Therapeutics
SRPT
$1.87B
| $512K | 2.45% |
28,500
| – | – |
2025 Q4
2 quarters
|
|
17
Humacyte
HUMA
$111M
| $507K | 2.43% |
650,000
| – | – |
2025 Q1
5 quarters
|
|
18
Kura Oncology
KURA
$833M
| $505K | 2.41% |
46,000
| – | – |
2025 Q3
3 quarters
|
|
19
Viatris
VTRS
$21B
| $440K | 2.1% |
27,700
| – | – |
2025 Q4
2 quarters
|
|
20
Dyne Therapeutics
DYN
$2.84B
| $400K | 1.91% |
18,000
| – | – |
2025 Q4
2 quarters
|
|
21
BridgeBio Pharma
BBIO
$13.3B
| $372K | 1.78% |
5,000
| – | – |
2024 Q2
8 quarters
|
|
22
Edgewise Therapeutics
EWTX
$4.12B
| $370K | 1.77% |
9,100
| – | – |
2025 Q4
2 quarters
|
|
23
Pacira BioSciences
PCRX
$1.45B
| $342K | 1.64% |
13,500
| – | – |
2025 Q4
2 quarters
|
|
24
Regenxbio
RGNX
$472M
| $319K | 1.52% |
26,600
| – | – |
2024 Q1
9 quarters
|
|
25
Rocket Pharmaceuticals
RCKT
$246M
| $294K | 1.41% |
86,000
| – | – |
2025 Q3
3 quarters
|
|
Similar funds
SCM
MPW
FS
VAM
SPC
SCM
HIIL
IACCGIA
Lion Point Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Lion Point Capital held 35 positions worth $20.9M, up 25% from $16.7M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Trading was light in Q2 2026: portfolio turnover was 0%. Lion Point Capital opened no new positions and made no exits, leaving the 35-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Lion Point Capital's biggest Q2 2026 reduction was Cue Biopharma, cutting an estimated $463K.
- Lion Point Capital's ten largest holdings make up 55% of its $20.9M portfolio in Q2 2026.
- Lion Point Capital opened 0 new positions and closed 0 in Q2 2026.
- Lion Point Capital's portfolio value rose 25% quarter-over-quarter to $20.9M.
Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.